FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2026 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

XBIZ Expo 2026 Pleasure Product Trade Show Schedule Announced

XBIZ is pleased to announce the release of the full show schedule for the XBIZ Expo pleasure product trade show, set to take place Jan. 8–12 at the Loews Hollywood Hotel.

Magic Silk Debuts 'Black Cherry' Collection

Magic Silk has introduced its new Black Cherry line of apparel.

Nexus Debuts 'Alpha Surge' Masturbator

Nexus has introduced Alpha Surge, its first stroker device.

Womanizer Drops 2 New Editions of 'Next' Stimulator

Womanizer has debuted two new versions of its Next clitoral stimulator, comprising the Bordeaux and Dusky Pink editions.

Lovense, Hustler Hollywood Partner for Demo Events

Lovense and Hustler Hollywood have partnered for a series of 16 in-store product demonstration events, starting Jan. 13.

Holiday Now Shipping 'Love to Love' Collection From Lovely Planet

Holiday Products is now shipping the Love to Love product line from Lovely Planet.

Nalpac Releases 2026 Valentine's Day Catalog

Nalpac has released its 70-page 2026 Valentine’s Day catalog, featuring hundreds of products.

Blush Expands 'Dr. Skin' Vibrator Collection

Blush has introduced three new designs to its Dr. Skin line of vibrators.

Svakom Launches 'KooSync' App

Svakom has launched its new KooSync interactive platform and app.

Full Circle Expands 'Dream Doll' Line, Adds Functional Mouths

Full Circle has introduced eight new models with functional mouths from its Dream Doll collection.

Show More